| Identification | Back Directory | [Name]
ML-7 HYDROCHLORIDE | [CAS]
110448-33-4 | [Synonyms]
ML-7
ML-7, HCl
ML-7 HYDROCHLORIDE
ML 7 hydrochloride, >=98%
1-(5-iodonaphthalene-1-sulfonyl)-1H-*hexahydro-1,
1-(5-IODONAPHTHALENE-1-SULFONYL)HOMOPIPERAZINE, HCL
1-(5-IODONAPHTHALENE-1-SULFONYL)-1H-*HEX AHYDRO-1,4-
1-(5-IODONAPHTHALENE-1-SULFONYL)-1H-HEXAHYDRO-1,4-DIAZEPINE
1-(5-IODONAPHTHALENE-1-SULFONYL)-1H-HEXAHYDRO-1,4-DIAZEPINE HCL
1-((5-Iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride
1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine, hyd
1-(5-IODONAPHTHALENE-1-SULFONYL)-1H-HEXAHYDRO-1,4-DIAZEPINE HYDROCHLORIDE
Hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine hydrochloride
Hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-1H-1,4-diazepine Monohydrochloride
1H-1,4-Diazepine, hexahydro-1-[(5-iodo-1-naphthalenyl)sulfonyl]-, Monohydrochloride | [Molecular Formula]
C15H18ClIN2O2S | [MDL Number]
MFCD00065524 | [MOL File]
110448-33-4.mol | [Molecular Weight]
452.74 |
| Chemical Properties | Back Directory | [Appearance]
Off-White to Yellow Fine Crystalline Solid | [Melting point ]
246-249°C dec. | [storage temp. ]
−20°C
| [solubility ]
insoluble in EtOH; ≥15.95 mg/mL in DMSO; ≥8.82 mg/mL in H2O with gentle warming and ultrasonic | [form ]
powder
| [color ]
white
|
| Hazard Information | Back Directory | [Chemical Properties]
Off-White to Yellow Fine Crystalline Solid | [Uses]
A potent and selective inhibitor of myosin light chain kinase. | [Description]
ML-7 inhibits smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 μM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. It exhibits a 10-fold more potent inhibition of MLCK than its parent compound ML-9 . | [Biochem/physiol Actions]
Selective myosin light chain kinase inhibitor. | [in vitro]
rats with myocardial infarction were intravenously infused with rhnrg-1. the cmlck expression and phosphorylated mlc-2v were up-regulated in rat treated with rhnrg-1 significantly. moreover, the restoration of rhnrg-1-induced sarcomeric organization in serum-free cultured neonatal rat cardiomyocytes with rhnrg-1 was inhibited by ml-7 [1]. | [in vivo]
administration of ml-7 from 10 min before ischemia to the first 10 min of reperfusion led to a significant recovery of heart contractility. gel analyses of two-dimensional electrophoresis revealed eight proteins with decreased levels in i/r hearts. six proteins involved in energy metabolism, which were cytochrome b-c1 complex subunit 1, atp synthase beta subunit, cytochrome c oxidase subunit, mitochondrial nadhdehydrogenase, nadhdehydrogenase iron-sulfur protein 8, and succinyl-coa ligase subunit. the other two protein levels decreased in i/r hearts, which were peroxiredoxin-2 and tubulin. in addition, ml-7 treatment increased the level of succinyl-coa ligase, which was a key enzyme involved in the citric acid cycle [2]. | [storage]
room temperature (desiccate) | [References]
[1] gu x,liu x,xu d,li x,yan m,qi y,yan w,wang w,pan j,xu y,xi b,cheng l,jia j,wang k,ge j,zhou m. cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. cardiovasc res.2010 nov 1;88(2):334-43.
[2] lin hb,cadete vj,sawicka j,wozniak m,sawicki g. effect of the myosin light chain kinase inhibitor ml-7 on the proteome of hearts subjected to ischemia-reperfusion injury. j proteomics.2012 sep 18;75(17):5386-95. |
|
| Company Name: |
Spectrum Chemical Manufacturing Corp.
|
| Tel: |
021-021-021-67601398-809-809-809 15221380277 |
| Website: |
www.spectrumchemical.com/oa_html/index.jsp?minisite=10020&respid=22372&language=us |
|